Liang Stephen

VRT CTO Liang Stephen sold 5,501 shares at $170.48; stock now at $169.57, down 8.9% in 30 days. Holdings reduced from 9,551 to 4,050 shares (-57.6%).

Liang Stephen, Chief Technology Officer & EVP, executed a substantial sale of 5,501 shares at $170.48 on 2025-11-24, reducing his post-transaction holdings to 4,050 shares—a -57.6% reduction from his pre-transaction position of 9,551 shares. The stock has since declined to $169.57 (current price), down 8.9% over the past 30 days and 14.9% from its 52-week high of $199.27. Across his cross-ticker open-market history, his 9 prior sells averaged +9.2% and +20.4% returns at the 30- and 90-day marks respectively, with a 22.22% well-timed sell rate; however, at VRT specifically, his track record is mixed—2 of 5 prior sales at this ticker were well-timed at the 90-day mark, while two 2024 November sales preceded declines of -9.1% to -9.6% and -30.4% to -30.8%. The company's fundamentals remain solid with $2.7B in latest quarterly revenue, $398.5M net income, and +16.7% annual revenue growth, though the P/E of 62.80 reflects elevated valuation. This substantial reduction in executive ownership, coinciding with near-52-week-high pricing and recent downward momentum, merits observation.

CTO Liang Stephen sells 43,683 shares at $115.83 avg, cutting VRT stake by 82.1%; stock up 35.6% in 90 days

Liang Stephen executed 2 separate sales totaling 43,683 shares for $5,060,017.74 on 2025-06-06, reducing his holdings from 53,234 to 9,551 shares—an 82.1% reduction. The sales occurred at $115.83 (blended average), near the stock's recent momentum peak; VRT has risen 35.6% over the past 90 days and 20.8% over 30 days, currently trading at $115.36, only 24.8% below its 52-week high of $153.49. His prior sales at VRT show mixed timing outcomes: three March 2024 sales each netted +15.9% to +16.6% gains 30 days later and +45.2% to +46.1% over 90 days (poorly timed), while two November 2024 sales each declined -9.1% to -9.6% at 30 days and -30.4% to -30.8% at 90 days (well-timed). The company's fundamentals show strong growth (revenue +16.7% year-over-year, $2.0B latest quarter, $164.5M net income) but a elevated P/E of 65.92 at a $44.0B market cap. The magnitude of this reduction—liquidating over four-fifths of his position near a 52-week high amid strong recent price momentum—differs materially from his typical smaller sales.

CTO Liang Stephen sold 86,619 shares ($11.4M) at blended avg $131.07, reducing VRT holdings by 81.6% to 19,551 shares.

Liang Stephen, CTO & EVP, executed 2 separate sales totaling 86,619 shares for $11,352,915.16 on 2024-11-26, at prices of $130.79 and $131.46 respectively. This represents a substantial liquidation: his holdings shrank from 106,170 shares (106.2K shares) to 19,551 shares (19.6K shares), a reduction of 81.6% of his pre-transaction position. The sales occurred near the 52-week high range—just 10.3% below the 52-week peak of $141.49—though current price at $126.94 is 3.4% below the transaction prices. His 5 prior sales at VRT on 2024-03-01 achieved average 90-day returns of +45.0% to +46.1%, indicating the stock rose substantially after those earlier sales; none of those 5 prior trades at VRT were well-timed at the 90-day mark. The current filing comes when VRT trades at a P/E of 81.90 with annual revenue growth of +20.6% and market cap of $47,645,150,824.48 ($47.6B).